title: Peripheral nervous system involvement in a haemodialysis patient treated with pegylated interferon.
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Ruiz-Fuentes
authors.forename: Agustina
authors.initials: A
authors.lastname: Rubert-Gómez De Quero
authors.forename: Carmen
authors.initials: C
authors.lastname: De Gracia-Guindo
authors.forename: Pilar
authors.initials: P
authors.lastname: Galindo-Sacristán
authors.forename: Antonio
authors.initials: A
authors.lastname: Osuna-Ortega
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D006435:Renal Dialysis
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a